GAD1 and epilepsy: In the first case, after the encephalitis is successfully treated, the risk of developing epilepsy is low (<15%), and the response to immunotherapy is substantially better than in those with central nervous system (CNS) disorders with Ab against intracellular proteins, which appear to be related to T cell-mediated mechanisms, such as glutamic acid decarboxylase (GAD) antibody-associated epilepsy, which are much less responsive to immunotherapy [3,4].